EmbryoGlue in IVF: Efficacy, Limits, and Role in Embryo Transfer
Key Takeaways
EmbryoGlue is a hyaluronic acid-enriched transfer medium associated with a modest probable improvement in live birth rates (~37-44% vs ~33%), recommended by ESHRE with monitoring of multiple-pregnancy rates but rated amber by HFEA.
Key evidence: Cochrane Review: Hyaluronan-Enriched Transfer Media (2020) HFEA: Hyaluronate-Enriched Transfer Medium Add-On Review (Amber Rating)
On this page
- EmbryoGlue in IVF
- What EmbryoGlue Actually Is
- The Mechanism: How It Is Proposed to Work
- What the Evidence Suggests
- Fresh vs Frozen Cycles
- Clinical Subgroup Hypotheses
- Safety Data and Limits
- FAQ
EmbryoGlue in IVF
EmbryoGlue is one of the better-known IVF add-ons. The name can make it sound more dramatic than it is.
It is not a glue in the everyday sense. It is a transfer medium enriched with hyaluronic acid, used around the time of embryo transfer.
According to the 2020 Cochrane Review, hyaluronan-enriched media may modestly improve live birth rates.
ESHRE recommends adding hyaluronan to the transfer medium. It also emphasises the need to monitor multiple-pregnancy rates.
The UK HFEA classifies this add-on as “amber” for most patients because study results conflict.
Dr. Aksoy’s Approach: EmbryoGlue is neither a miracle cure nor a marketing gimmick.
I view high-concentration hyaluronan transfer media as a modest, evidence-backed complementary option. Its use can be discussed individually in situations such as unexplained recurrent implantation failure or a complex transfer cycle.
It is not a proven requirement for a specific subgroup or a substitute for embryo quality.
What EmbryoGlue Actually Is
EmbryoGlue is a specialised laboratory culture and transfer medium. It contains a high concentration of hyaluronic acid.
Hyaluronic acid occurs naturally throughout the female reproductive tract. Levels peak in uterine secretions during the implantation window.
Key product details:
- Composition: Contains recombinant human albumin or purified serum albumin to support embryo nutrition.
- Natural Mimicry: Increases medium viscosity to closely match natural uterine secretions at implantation.
- Clinical Role: Used immediately before and during embryo transfer to support initial embryo attachment.
The Mechanism: How It Is Proposed to Work
The proposed benefit rests on two clinical mechanisms:
- Viscosity Effect: Thickened medium reduces involuntary fluid displacement inside the uterine cavity during catheter withdrawal.
- Cellular Receptor Binding: Hyaluronic acid binds to CD44 cell receptors present on both the blastocyst surface and the endometrial lining.
Biological plausibility does not guarantee individual success, nor does it correct underlying endometrial defects in a stimulated cycle.
What the Evidence Suggests
The 2020 Cochrane Review pooled 26 randomised controlled trials involving more than 6,700 patients.
It concluded that hyaluronan-enriched media probably improve live birth rates. The certainty of this evidence was moderate:
| Outcome | Standard Medium | With Hyaluronan (95% CI) | Relative Effect (RR) | Certainty of Evidence (Cochrane) |
|---|---|---|---|---|
| Live Birth Rate | ~33.0% | ~37.0% to 44.0% | RR 1.21 (1.11 – 1.31) | Moderate certainty |
| Clinical Pregnancy | ~35.0% | ~38.0% to 43.0% | RR 1.16 (1.09 – 1.23) | Moderate certainty |
| Miscarriage Rate | Baseline | Possible reduction (effect uncertain) | RR 0.82 (0.67 – 1.00) | Low (uncertain when limited to low risk-of-bias trials) |
| Multiple Pregnancy | Baseline | Increased in trials where multiple embryos were transferred | RR 1.45 (1.24 – 1.70) | Moderate certainty |
Elective single embryo transfer (eSET) remains the primary way to reduce multiple-pregnancy risk, regardless of transfer medium.
Fresh vs Frozen Cycles
- Fresh transfers: A biological rationale exists, but trial data does not prove that hyaluronan media “correct” hormonal changes from stimulation.
- Frozen transfers (FET): Observational reports explore possible benefits. They do not establish a routine indication.
Clinical Subgroup Hypotheses
Clinicians may discuss EmbryoGlue as an option in specific cases:
- Recurrent Implantation Failure (RIF): Discussed as a complementary option when previous transfers failed.
- Complex Prognosis: Evaluated individually when overall cycle prognosis is guarded.
- Difficult Transfers: Managing difficult transfers relies primarily on catheter technique rather than transfer media.
Safety Data and Limits
No additional clinical safety risks have been identified with hyaluronan transfer media.
This does not mean that the add-on is necessary for every patient.
However, EmbryoGlue cannot:
- Correct chromosomal or genetic abnormalities in embryos.
- Replace morphological or genetic embryo selection.
- Overcome severe uncorrected uterine structural defects.
- Guarantee embryo implantation.
Related Reading
- Embryo Transfer in IVF: What Matters Most for Success
- Embryo Transfer Timing in IVF: When Day 3 or Day 5 Makes More Sense
- Fresh vs Frozen Embryo Transfer: How Doctors Usually Choose
FAQ
Does EmbryoGlue guarantee a better IVF result?
No. Population data suggest a modest probable benefit.
Individual outcomes still depend on embryo quality, age, and endometrial receptivity.
Does EmbryoGlue increase twin risk?
It does not cause monozygotic twin splitting. In trial data, any increase in multiple pregnancy related to transferring more than one embryo.
Does EmbryoGlue replace PGT-A genetic testing?
No. EmbryoGlue has no effect on embryo genetics.
Some chromosomal abnormalities prevent implantation or increase early loss risk. Their consequences depend on the specific abnormality. PGT-A is not a routine solution for every patient.
How is it used in the laboratory?
The embryo is placed in the enriched medium before transfer. The laboratory follows validated protocols and product instructions.
For the patient, the clinical transfer procedure is identical.
Sources
- Cochrane Review: Hyaluronan-enriched transfer media for assisted reproduction (2020)
- HFEA: Hyaluronate-enriched transfer medium (EmbryoGlue) add-on review — Amber rating
- ESHRE Guidelines on IVF Add-ons (2023)
- FET Conference Abstract (2024) (Note: conference abstract; does not establish level-1 causal proof).
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.